Loading...
•
Jun 30, 2021
Rigel Q2 2021 Earnings Report
Reported financial results for the second quarter ended June 30, 2021, including sales of TAVALISSE.
Key Takeaways
Rigel Pharmaceuticals reported a net loss of $13.8 million for the second quarter of 2021, with total revenues of $26.3 million, including TAVALISSE net product sales of $17.1 million.
TAVALISSE sales are growing as Rigel accesses more clinicians in-person.
Rigel is expanding its commercial team to increase impact as physicians and patients return to the clinic.
Phase 3 clinical trial of fostamatinib in hospitalized COVID-19 patients is rapidly enrolling.
Phase 3 clinical trial of fostamatinib in wAIHA is nearing its enrollment goal.
Rigel
Rigel
Rigel Revenue by Segment
Revenue by Segment
Contract revenues from collaborations Revenue
CapyFin.com Forward Guidance
Rigel is well-positioned to execute on several key milestones that have the potential to be important inflection points for the company.